2000
DOI: 10.1590/s0100-879x2000000700009 View full text |Buy / Rent full text
|
|

Abstract: Clinical trials indicate that amifostine may confer protection on various normal tissues without attenuating anti-tumor response. When administered prior to chemotherapy or radiotherapy, it may provide a broad spectrum of cytoprotection including against alkylating drugs. The mechanism of protection resides in the metabolism at normal tissue site by membrane-bound alkaline phosphatase. Toxicity of this drug is moderate with hypotension, nausea and vomiting, and hypocalcemia being observed. We report a phase II… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
0
17
0
1

Publication Types

Select...

Relationship

0
0

Authors

Journals